Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.
Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, Sperduti I, Gelibter A, Scagliotti GV, Cognetti F, Giannarelli D. Bria E, et al. Ann Oncol. 2011 Oct;22(10):2277-85. doi: 10.1093/annonc/mdq742. Epub 2011 Feb 16. Ann Oncol. 2011. PMID: 21325444 Free PMC article. Review.
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors.
Pilotto S, Sperduti I, Novello S, Peretti U, Milella M, Facciolo F, Vari S, Leuzzi G, Vavalà T, Marchetti A, Mucilli F, Crinò L, Puma F, Kinspergher S, Santo A, Carbognin L, Brunelli M, Chilosi M, Scarpa A, Tortora G, Bria E. Pilotto S, et al. Among authors: bria e. J Thorac Oncol. 2015 Sep;10(9):1341-1348. doi: 10.1097/JTO.0000000000000628. J Thorac Oncol. 2015. PMID: 26200453 Free article.
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
Caccese M, Ferrara R, Pilotto S, Carbognin L, Grizzi G, Caliò A, Brunelli M, Cuppone F, Petraglia S, Scarpa A, Tortora G, Bria E. Caccese M, et al. Among authors: bria e. Expert Opin Pharmacother. 2016 Dec;17(17):2253-2266. doi: 10.1080/14656566.2016.1242578. Epub 2016 Oct 8. Expert Opin Pharmacother. 2016. PMID: 27682212 Review.
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.
Simbolo M, Centonze G, Ali G, Garzone G, Taormina S, Sabella G, Ciaparrone C, Mafficini A, Grillo F, Mangogna A, Volante M, Mastracci L, Fontanini G, Pilotto S, Bria E, Infante M, Capella C, Rolli L, Pastorino U, Milella M, Milione M, Scarpa A. Simbolo M, et al. Among authors: bria e. ESMO Open. 2022 Feb;7(1):100308. doi: 10.1016/j.esmoop.2021.100308. Epub 2021 Dec 21. ESMO Open. 2022. PMID: 34952268 Free PMC article.
To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
Orlandi A, Mastrantoni L, Bria E, Tortora G. Orlandi A, et al. Among authors: bria e. Ann Oncol. 2024 Aug;35(8):748-749. doi: 10.1016/j.annonc.2024.05.544. Epub 2024 Jun 3. Ann Oncol. 2024. PMID: 38838845 No abstract available.
2-weekly docetaxel: issues for clinical practice.
Massari F, Maines F, Bria E, Galligioni E, Caffo O, Tortora G. Massari F, et al. Among authors: bria e. Cancer Biol Ther. 2015;16(1):17-8. doi: 10.4161/15384047.2014.987534. Cancer Biol Ther. 2015. PMID: 25456569 Free PMC article.
409 results